Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16729887 | 0.84 | LGALS8 (0.30) | LGALS8 | |
| SCHEMBL18390208 | 0.84 | LGALS8 (0.30) | LGALS8 | |
| SCHEMBL21533368 | 0.79 | LGALS8 (0.32) | LGALS8 | |
| SCHEMBL15763702 | 0.79 | — | — | |
| SCHEMBL19631498 | 0.78 | LGALS8 (0.33) | LGALS8 | |
| SCHEMBL12950636 | 0.78 | — | — | |
| SCHEMBL21561701 | 0.78 | — | — | |
| SCHEMBL23417369 | 0.77 | MAPK1 (0.42) | LGALS8 | |
| SCHEMBL22605123 | 0.77 | MAPK1 (0.42) | LGALS8 | |
| SCHEMBL22605122 | 0.77 | MAPK1 (0.42) | LGALS8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230126157-A1 | MIRNA-485 INHIBITOR FOR GENE UPREGULATION | BIORCHESTRA CO., LTD. (KR) | 2023-04-27 | — | — | US | disclosed |
| US-11155816-B2 | Oligonucleotide conjugates | ROCHE INNOVATION CENTER COPENHAGEN A/S (CH) | 2021-10-26 | — | — | US | disclosed |
| US-11091764-B2 | Antisense oligomers targeting PCSK9 | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2021-08-17 | — | — | US | disclosed |
| US-20210238601-A1 | Oligonucleotide Conjugates | ROCHE INNOVATION CENTER COPENHAGEN A/S (CH) | 2021-08-05 | — | — | US | disclosed |
| US-20200248186-A1 | ANTISENSE OLIGOMERS TARGETING PCSK9 | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2020-08-06 | — | — | US | disclosed |
| US-9879265-B2 | Oligonucleotide conjugates | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2018-01-30 | — | — | US | disclosed |
| WO-2010001349-A8 | RNA ANTAGONISTS TARGETING HSP27 | SANTARIS PHARMA A/S (DK) | 2010-03-11 | — | — | WO | disclosed |
| WO-2010001349-A1 | RNA ANTAGONISTS TARGETING HSP27 | SANTARIS PHARMA A/S (DK) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230126157-A1 | MIRNA-485 INHIBITOR FOR GENE UPREGULATION | NRP1, SORT1, NR4A3 | LGALS8 3438/4885 |
| US-11091764-B2 | Antisense oligomers targeting PCSK9 | PCSK9, PCSK7, PCSK6 | LGALS8 1504/4885 |
| US-20200248186-A1 | ANTISENSE OLIGOMERS TARGETING PCSK9 | PCSK9, PCSK7, PCSK6 | LGALS8 1504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.